Acadia Pharmaceuticals (ACAD) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.
- Acadia Pharmaceuticals' Income towards Parent Company rose 11913.63% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10333.39%. This contributed to the annual value of $226.5 million for FY2024, which is 46919.75% up from last year.
- According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Income towards Parent Company is $71.8 million, which was up 11913.63% from $26.7 million recorded in Q2 2025.
- Acadia Pharmaceuticals' Income towards Parent Company's 5-year high stood at $143.8 million during Q4 2024, with a 5-year trough of -$113.1 million in Q1 2022.
- For the 5-year period, Acadia Pharmaceuticals' Income towards Parent Company averaged around -$5.3 million, with its median value being -$14.5 million (2021).
- Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 13948.56% in 2023, then skyrocketed by 289820.47% in 2024.
- Over the past 5 years, Acadia Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$43.1 million in 2021, then rose by 3.29% to -$41.7 million in 2022, then soared by 209.77% to $45.7 million in 2023, then soared by 214.23% to $143.8 million in 2024, then plummeted by 50.05% to $71.8 million in 2025.
- Its Income towards Parent Company stands at $71.8 million for Q3 2025, versus $26.7 million for Q2 2025 and $19.0 million for Q1 2025.